TransMED analyzes patient data from similar diseases across multiple sources to understand COVID-19 patient outcome risk factors.

The Washington State Academy of Sciences added six people from PNNL to its 2022 class of inductees.

The virus that causes COVID-19 takes over the body’s fat-processing system and boosts cellular triglycerides as it causes disease.

A new, state-of-the-art training facility in Larnaca, Cyprus provides unique training opportunities for border security officials from partner nations.

PNNL Hydrogen Safety Panel supports a fundamental hydrogen safety credential deployed through the Center for Hydrogen Safety.

The Department of Homeland Security Science and Technology Virtual First Responder Capitol Hill Showcase highlighted PNNL work in fentanyl detection standards and database libraries.

PNNL scientists have developed a new mass spectrometry method for in-depth analysis of proteins in individual cells.

The paper was recognized by the Society of Toxicology’s Medical Device and Combination Product Specialty Section.

Proteomics revealed molecular mechanisms by which the drug Verapamil could prolong beta cell function in early-onset type 1 diabetes patients.

Sarah Frazar, a group manager in the National Security Directorate at PNNL, was recently elected Vice Chair of the Board of Trustees for the World Affairs Council of Seattle.

Study highlights microbiome’s role in regulating xenobiotic metabolism.

Development of a one-meter path length miniature ion mobility spectrometer based on multilevel structures for lossless ion manipulations.

Governor Inslee announced the appointment of Karin Rodland to the Board of Directors of the Andy Hill Cancer Research Endowment Fund.

The eighth Arab-American Frontiers of Science, Engineering, and Medicine Symposium, co-organized by PNNL engineer and research line manager Leonard Pease, brought together multi-disciplinary researchers from around the globe.

Studying MERS-CoV may lead to better treatments for a host of respiratory illnesses, including the many variants of COVID-19.

A study raises questions about how far droplets, like those that carry the virus that causes COVID-19, can travel before becoming harmless.

PNNL scientists are protecting first responders and others by expanding what’s known about fentanyl, the driver of the opioid epidemic.

Researchers characterize protein signatures that indicate Acute Kidney Injury in COVID-19 patients.

Simulations reveal advantages of using new model vs. allometric scaling for risk assessment.

From water purification, to better batteries and tools to foil a cyberattack—a look back at how PNNL helped to invent a brighter and better future over the last year.